|
- Ionis announces positive olezarsen topline results from Phase 3 study . . .
Ionis plans to file a New Drug Application in early 2024 with the U S Food and Drug Administration (FDA) in addition to EU regulatory filings If approved, olezarsen would be the first available treatment in the U S for FCS , a rare, debilitating genetic disease that can lead to acute, potentially
- Ionis poised for continued momentum in 2024 with product launches and . . .
Ionis expects to have six independent neurology programs in clinical development by year-end 2024, including new programs in rare pediatric diseases and severe dementias, which currently have no approved therapies
- Ionis Earns $5 Million Milestone Payment from Biogen for Advancing a . . .
Ionis is the leading company in RNA-targeted drug discovery and development focused on developing drugs for patients who have the highest unmet medical needs, such as those patients with severe and rare diseases
- Ionis and AstraZeneca Advance New Drug for NASH
announced that it has licensed IONIS-AZ6-2 5-L Rx, or AZD2693, to AstraZeneca (NYSE: AZN) following advancement of the drug into development IONIS-AZ6-2 5-L Rx is designed to inhibit an undisclosed target to treat patients with nonalcoholic steatohepatitis (NASH) In conjunction with this
- Webcast Alert: Isis Pharmaceuticals First Quarter 2012 Financial . . .
The Investor Relations website contains information about Ionis Pharmaceuticals, Inc 's business for stockholders, potential investors, and financial analysts
- Ionis reports second quarter 2024 financial results
Ionis' operating expenses increased in the second quarter and first half of 2024 compared to the same periods in 2023, consistent with expectations SG A expenses increased year over year primarily due to the launch of WAINUA in the U S and launch preparation activities for olezarsen and
- KEY TAKEAWAY - Ionis Pharmaceuticals, Inc.
In December 2021, Ionis launched the clinical process that the company hopes will one day deliver therapeutic benefit to people living with Angelman syndrome (AS), a rare and devastating neurodevelopmental disease
- Ionis announces positive results from fesomersen development program . . .
Fesomersen, (formerly IONIS-FXI-L Rx) is an investigational antisense medicine designed by Ionis to reduce the production of Factor XI, a clotting factor produced in the liver that is an important component of the coagulation pathway High levels of Factor XI increase the risk of blood clot formation inside blood vessels (thrombosis), which can
|
|
|